close
1.

電子ブック
ＥＢ
1. Privacy and Identity Management : 17th IFIP WG 9. 2, 9. 6/11. 7, 11. 6/SIG 9. 2. 2 International Summer School, Privacy and Identity 2022, Virtual Event, August 30-September 2, 2022, Proceedings
Felix. Bieker
出版情報: SpringerLink Books - AutoHoldings , Cham : Springer International Publishing AG, 2023
所蔵情報: loading…
2.

電子ブック
ＥＢ
2. 2023 2nd International Conference on Electronics, Energy and Measurement (IC2EM)
出版情報: IEEE Electronic Library (IEL) Conference Proceedings , IEEE, 2023
所蔵情報: loading…
3.

電子ブック
ＥＢ
3. Learning to Quantify
Esuli, Alessandro Fabris, Alejandro Moreo, Fabrizio Sebastiani
出版情報: SpringerLink Books - AutoHoldings , Springer International Publishing, 2023
所蔵情報: loading…
目次情報: 続きを見る
The Case for Quantification / 1：
Class Distributions and Their Estimation / 1.1：
The Suboptimality of Classify and Count / 1.2：
Notational Conventions / 1.3：
Quantification Problems / 1.4：
Dataset Shift and Quantification / 1.5：
Types of Dataset Shift and Their Relation to Quantification / 1.5.1：
Quantification and Bias Mitigation / 1.6：
Structure of This Book / 1.7：
Applications of Quantification / 2：
Improving Classification Accuracy / 2.1：
Word Sense Disambiguation / 2.1.1：
Fairness / 2.2：
Improving Fairness / 2.2.1：
Measuring Fairness / 2.2.2：
Sentiment Analysis / 2.3：
Social and Political Sciences / 2.4：
Market Research / 2.5：
Epidemiology / 2.6：
Ecological Modelling / 2.7：
Resource Allocation / 2.8：
Evaluation of Quantification Algorithms / 3：
Measures for Evaluating SLQ, BQ, and MLQ / 3.1：
Properties of Evaluation Measures for SLQ, BQ, and MLQ / 3.1.1：
Bias / 3.1.2：
Absolute Error and its Variants / 3.1.3：
Relative Absolute Error and its Variants / 3.1.4：
Kullback-Leibler Divergence and its Variants / 3.1.5：
Which Measure is the Best for SLQ? / 3.1.6：
Measures for Evaluating OQ / 3.2：
Earth Mover's Distance / 3.2.1：
Root Normalised Order-Aware Divergence / 3.2.2：
Measures for Evaluating Regression Quantification / 3.3：
Experimental Protocols for Evaluating Quantification / 3.4：
Natural Prevalence Protocol (NPP) / 3.4.1：
Artificial Prevalence Protocol (APP) / 3.4.2：
A Variant of the APP Based on the Kraemer Algorithm / 3.4.3：
Should we Use the NPP or the APP? / 3.4.4：
Model Selection in Quantification / 3.5：
Methods for Learning to Quantify / 4：
Maximum Likelihood Prevalence Estimation / 4.1：
Aggregative Methods Based on General-Purpose Learners / 4.2：
Classify and Count / 4.2.1：
Probabilistic Classify and Count / 4.2.2：
Adjusted Classify and Count / 4.2.3：
Probabilistic Adjusted Classify and Count / 4.2.4：
X, MAX, and Threshold@0.50 / 4.2.5：
Median Sweep / 4.2.6：
The Ratio Estimator / 4.2.7：
Mixture Models / 4.2.8：
Expectation Maximisation for Quantification / 4.2.9：
Class Distribution Estimation / 4.2.10：
Ensemble Methods for Quantification / 4.2.11：
QuaNet / 4.2.12：
Aggregative Methods Based on Special-Purpose Learners / 4.3：
Methods Based on Explicit Loss Minimisation / 4.3.1：
Quantification Trees and Quantification Forests / 4.3.2：
Non-Aggregative Methods / 4.4：
The README Method / 4.4.1：
The iSA Method / 4.4.2：
The README2 Method / 4.4.3：
The HDx Method / 4.4.4：
The MMD-RKHS Method / 4.4.5：
The Uncertainty-Aware Generative Model / 4.4.6：
Deep Quantification Network / 4.4.7：
Advanced Topics / 5：
Ordinal Quantification / 5.1：
Regression Quantification / 5.2：
Cross-Lingual Quantification / 5.3：
Quantification for Networked Data / 5.4：
Cost Quantification / 5.5：
Quantification in Data Streams / 5.6：
One-Class Quantification / 5.7：
Confidence Intervals for Class Prevalence Estimates / 5.8：
The Quantification Landscape / 6：
Historical Development / 6.1：
The Trajectory of Quantification / 6.1.1：
Shared Tasks / 6.1.2：
Software / 6.2：
Publicly Available Implementations / 6.2.1：
QuaPy: A Comprehensive Framework for Quantification / 6.2.2：
How Do Different Quantification Methods Fare? / 6.3：
A Tour of Experimental Results / 6.3.1：
Visualisation Tools for the Analysis of Results / 6.3.2：
Related Tasks / 6.4：
Links to Existing Tasks / 6.4.1：
A Possible Variant of the Quantification Task / 6.4.2：
The Road Ahead / 7：
Bibliography
Index
The Case for Quantification / 1：
Class Distributions and Their Estimation / 1.1：
The Suboptimality of Classify and Count / 1.2：
4.

電子ブック
ＥＢ
4. 1349-2021/Cor 1-2022 - IEEE Guide for the Application of Electric Machines in Zone 2 and Class I, Division 2 Hazardous (Classified) Locations - Corrigendum 1
出版情報: IEEE Electronic Library (IEL) Standards , IEEE, 2023
所蔵情報: loading…
5.

電子ブック
ＥＢ
5. 62530-2-2023 - IEEE/IEC International Standard--SystemVerilog--Part 2: Universal Verification Methodology Language Reference Manual
出版情報: IEEE Electronic Library (IEL) Standards , IEEE, 2023
所蔵情報: loading…
6.

図書
図書
6. Proceedings of the Canadian Society of Civil Engineering Annual Conference 2022 (v. 2, set 2)
Rishi Gupta ... [et al.], editors
出版情報: Cham : Springer, c2023  xviii p., p. 623-1214 ; 25 cm
シリーズ名: Lecture notes in civil engineering ; v. 348
所蔵情報: loading…
7.

学位論文
学位
7. Thin films of CaZn[2]N[2] and Cul for optoelectronics
Masatake Tsuji
出版情報: 東京 : 東京工業大学, 2023  1 online resource
所蔵情報: loading…
8.

電子ブック
ＥＢ
8. Pathogenic coronaviruses of humans and animals : SARS, MERS, COVID-19, and animal coronaviruses with zoonotic potential
Lisa A. Beltz
出版情報: London : Academic Press, 2023  1 online resource
所蔵情報: loading…
目次情報: 続きを見る
List of figures
List of tables
Acknowledgments
Introduction / 1：
Of viruses and men / 1.1：
Coronaviruses of humans / 1.1.1：
Factors affecting zoonotic transmission of coronaviruses / 1.1.2：
A brief introduction to viruses / 1.2：
Characteristics of viruses / 1.2.1：
Overview of mutations and recombination in viruses / 1.2.2：
Viruses and their host receptors / 1.2.3：
Baltimore class IV viruses / 1.2.4：
Viruses, diseases, and pandemics-victories and failures / 1.2.5：
Vaccination-then and now / 1.2.6：
Comparison of viruses, bacteria, and eukaryotic cells / 1.2.7：
A brief introduction to the immune system / 1.3：
Introduction to the innate immune system / 1.3.1：
The cells of the innate immune system / 1.3.2：
Introduction to the adaptive immune system / 1.3.3：
The cells of the adaptive immune system / 1.3.4：
Cytokines and chemokines / 1.3.5：
Antibodies / 1.3.6：
Introduction to coronaviruses / 1.4：
Coronavirus genomic and subgenomic RNA / 1.4.1：
Increasing genetic diversity by mutation and recombination in coronaviruses / 1.4.2：
Production of recombinant, chimeric coronaviruses / 1.4.3：
Coronaviruses' structural proteins / 1.4.4：
Coronaviruses' nonstructural proteins / 1.4.5：
A brief summary of the coronavirus life cycle / 1.4.6：
Viral transmission / 1.4.7：
Coronaviruses and disease / 1.5：
Coronaviruses and respiratory disease / 1.5.1：
Coronaviruses and central nervous system disease / 1.5.2：
Other coronavirus disease manifestations / 1.5.3：
Categories of coronaviruses / 1.6：
Coronavirus genera / 1.6.1：
Coronaviruses of animals and zoonotic disease potential / 1.6.2：
Treatment of coronavirus diseases / 1.7：
Chloroquine / 1.7.1：
Nucleic acid analogs / 1.7.2：
Traditional medicinal compounds / 1.7.3：
Prevention of coronavirus infection / 1.8：
References
Severe acute respiratory syndrome (SARS) / 2：
A brief overview of the 2002-2003 severe acute respiratory syndrome-coronavirus outbreak / 2.1：
Phases of the 2002-2003 outbreak / 2.1.2：
"Wet Markets" and wild cats and dogs / 2.1.3：
The severe acute respiratory syndrome-coronavirus spike protein and its angiotensin-converting enzyme 2 receptor / 2.1.4：
The history of severe acute respiratory syndrome / 2.2：
Severe acute respiratory syndrome-the disease / 2.3：
An overview of severe acute respiratory syndrome / 2.3.1：
Severe acute respiratory syndrome and the respiratory system / 2.3.2：
Severe acute respiratory syndrome and the cardiovascular system / 2.3.3：
Severe acute respiratory syndrome and the skeletal system / 2.3.4：
Severe acute respiratory syndrome and the digestive system / 2.3.5：
Severe acute respiratory syndrome and the urinary system / 2.3.6：
Severe acute respiratory syndrome and nervous system / 2.3.7：
Severe acute respiratory syndrome and the endocrine system / 2.3.8：
Severe acute respiratory syndrome, the reproductive system, and sex-related disease severity / 2.3.9：
The causative virus / 2.4：
An overview of severe acute respiratory syndrome-coronavirus / 2.4.1：
Entry of severe acute respiratory syndrome-coronavirus into cells / 2.4.2：
Viral polyproteins and proteases / 2.4.3：
Severe acute respiratory syndrome-coronavirus and the ubiquitin-pathway / 2.4.4：
Severe acute respiratory syndrome-coronavirus and the unfolded protein response / 2.4.5：
Severe acute respiratory syndrome-coronavirus open reading frame 8 / 2.4.6：
Severe acute respiratory syndrome and small non-coding RNAs / 2.4.7：
Severe acute respiratory syndrome-coronavirus and bats / 2.4.8：
Transmission of severe acute respiratory syndrome between humans / 2.4.9：
Severe acute respiratory syndrome-coronavirus in the external environment / 2.4.10：
The immune response / 2.5：
Introduction to severe acute respiratory syndrome-coronavirus and the immune system / 2.5.1：
Severe acute respiratory syndrome-coronavirus and the adaptive immune response / 2.5.2：
Severe acute respiratory syndrome-coronavirus, cytokines, and chemokines / 2.5.3：
Severe acute respiratory syndrome and interferons / 2.5.4：
The severe acute respiratory syndrome-coronavirus ? protein and the immune response / 2.5.5：
Severe acute respiratory syndrome-coronavirus and the innate immune response / 2.5.6：
Animal models and the immune response to severe acute respiratory syndrome / 2.5.7：
Severe acute respiratory syndrome-coronavirus and escape from the immune response / 2.5.8：
Severe acute respiratory syndrome immunopathology / 2.5.9：
Treatment options / 2.6：
Diagnosis / 2.7：
Prevention / 2.8：
Physical means of prevention / 2.8.1：
Immunization / 2.8.2：
Active immunization / 2.8.3：
Surveillance / 2.9：
Middle Eastern respiratory syndrome / 3：
Introduction to Middle Eastern respiratory syndrome and Middle Eastern respiratory syndrome coronavirus / 3.1：
A brief introduction to Middle Eastern respiratory syndrome / 3.1.1：
A brief Introduction to Middle Eastern respiratory syndrome-coronavirus / 3.1.2：
Transmission of Middle Eastern respiratory syndrome-coronavirus to humans / 3.1.3：
The history / 3.2：
The disease / 3.3：
Introduction to Middle Eastern respiratory syndrome in humans / 3.3.1：
The mortally rate of Middle Eastern respiratory Syndrome / 3.3.2：
Middle Eastern respiratory syndrome and the respiratory system / 3.3.3：
Middle Eastern respiratory syndrome and the kidneys / 3.3.4：
Middle Eastern respiratory syndrome and the cardiovascular system / 3.3.5：
Middle Eastern respiratory syndrome and the nervous system / 3.3.6：
Risk factors for Middle Eastern respiratory syndrome in humans / 3.3.7：
Middle Eastern respiratory syndrome-coronavirus classification / 3.4：
Genetic variation in Middle Eastern respiratory syndrome-coronavirus / 3.4.2：
DPP4 and the viral S protein in Middle Eastern respiratory syndrome-coronavirus and Middle Eastern respiratory syndrome-coronavirus-like viruses of humans and animals / 3.4.3：
Other molecules involved in Middle Eastern respiratory syndrome-coronavirus entry into its target cells / 3.4.4：
Animal hosts of Middle Eastern respiratory syndrome-coronavirus / 3.5：
Middle Eastern respiratory syndrome-coronavirus and bats as reservoir hosts / 3.5.1：
Middle Eastern respiratory syndrome-coronavirus and dromedary camels / 3.5.2：
Middle Eastern respiratory syndrome and Bactrian camels / 3.5.3：
Middle Eastern respiratory syndrome-coronavirus and other camelids / 3.5.4：
Middle Eastern respiratory syndrome-coronavirus in other agricultural animals / 3.5.5：
Middle Eastern respiratory syndrome-coronavirus and other animals / 3.5.6：
Animal models of Middle Eastern respiratory syndrome / 3.5.7：
Middle Eastern respiratory syndrome and T lymphocytes / 3.6：
Middle Eastern respiratory syndrome, B lymphocytes, and Antibodies / 3.6.2：
Middle Eastern respiratory syndrome, dendritic cells, monocytes/macrophages, and neutrophils / 3.6.3：
Middle Eastern respiratory syndrome, cytokines, and chemokines / 3.6.4：
Middle Eastern respiratory syndrome and interferons / 3.6.5：
Middle Eastern respiratory syndrome-coronavirus escape mechanisms / 3.6.6：
Treatment / 3.7：
Generalized, physical treatments / 3.8.1：
Introduction to Middle Eastern respiratory syndrome drug treatment options / 3.8.2：
Decontamination of environmental surfaces / 3.9：
Vaccination / 3.10.2：
COVID-19 / 4：
Severe acute respiratory syndrome coronavirus and other human coronaviruses / 4.1：
Number of cases, deaths, and vaccinations / 4.1.2：
Spread of severe acute respiratory coronavirus-2 / 4.1.3：
Factors affecting determination of COVID-19 cases / 4.1.4：
Unprepared / 4.1.5：
Severe acute respiratory syndrome coronavirus-2 and animal hosts / 4.1.6：
History / 4.2：
Introduction to COVID-19 / 4.3：
COVID-19 and the respiratory system / 4.3.2：
COVID-19, smoking, and nicotine use / 4.3.3：
COVID-19 and the cardiovascular system / 4.3.4：
COVID-19, endothelial dysfunction, complement, and coagulation / 4.3.5：
COVID-19 and neurological disease / 4.3.6：
COVID and psychiatric disease / 4.3.7：
COVID-19 and special senses / 4.3.8：
COVID-19 and the endocrine system / 4.3.9：
COVID-19 and the urinary system / 4.3.10：
COVID-19 and the digestive system / 4.3.11：
COVID-19 and the integumentary system / 4.3.12：
COVID-19 and biological sex / 4.3.13：
COVID-19 case number and seventy in children and adults / 4.3.14：
Multisystem inflammatory syndrome in children / 4.3.15：
Long COVID syndrome (chronic or post-COVID-19 syndrome) / 4.3.16：
The role of genetic factors in COVID-19 / 4.3.17：
Introduction to severe acute respiratory syndrome coronavirus-2 / 4.4：
The question of the reservoir and intermediate hosts of severe acute respiratory syndrome coronavirus-2 / 4.4.2：
Comparison of severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2 / 4.4.3：
Transmission of severe acute respiratory syndrome coronavirus-2 / 4.4.4：
Severe acute respiratory syndrome coronavirus-2 mutations / 4.4.5：
COVID-19 and the adaptive immune response / 4.5：
COVID-19 immunopathology-IL-17 and the cytokine storm / 4.5.2：
COVID-19 and the innate immune response / 4.5.3：
COVID-19 and autoimmune disorders / 4.5.4：
Diagnosis and surveillance / 4.6：
RNA-based (genetic) tests / 4.6.1：
Antibody-based (serological) tests for severe acute respiratory syndrome coronavirus-2 infection / 4.6.2：
Viral neutralization tests / 4.6.3：
Medications and monoclonal antibodies / 4.6.4：
COVID-19, micronutrients, and vitamin D / 4.7.2：
COVID-19 and zinc / 4.8.1：
COVID-19 and copper / 4.8.2：
COVID-19 and selenium / 4.8.3：
COVID-19 and iron / 4.8.4：
COVID-19 and vitamin D / 4.8.5：
Rapid, mass scanning measures / 4.9：
Personal protective equipment and social distancing / 4.9.2：
Hand hygiene / 4.9.3：
Decontamination of infected surfaces / 4.9.4：
COVID-19, quarantine, and closure of businesses, schools, and recreational areas / 4.9.5：
Natural immunity / 4.9.6：
Vaccines against severe acute respiratory syndrome coronavirus-2 infection / 4.9.7：
Further reading
Coronaviruses of wild and semidomesticated animals with the potential for zoonotic transmission / 5：
Transmission of coronaviruses / 5.1：
Genetic recombination between coronavirus animal hosts / 5.2.1：
The viral spike protein and host coronavirus receptors / 5.2.2：
Introduction to coronaviruses and intracellular signaling pathways / 5.2.3：
Coronavirus vaccines / 5.2.4：
Severe acute respiratory syndrome virus-2 and its animal hosts / 5.2.5：
Coronaviruses of bats / 5.3：
Introduction to bat coronaviruses / 5.3.1：
WIV1, WIV16, SARS-CoV, and adaptation to different host species / 5.3.2：
Chimeric bat coronaviruses and severe acute respiratory syndrome virus / 5.3.3：
The spike protein of bat and human coronaviruses and angiotensin-converting enzyme 2 / 5.3.4：
Bat Coronaviruses, MERS-CoV, and dipeptidyl peptidase IV / 5.3.5：
Characteristics of coronavirus species of hats / 5.3.6：
Prevention against bat coronavirus infection / 5.3.7：
Coronaviruses of rodents / 5.4：
Introduction to coronaviruses of rodents / 5.4.1：
Mouse hepatitis virus / 5.4.2：
Rat coronavirus / 5.5：
Introduction to rat coronavirus / 5.5.1：
Rat coronavirus and disease / 5.5.2：
Rat coronavirus and the immune response / 5.5.3：
Other coronaviruses of rodents / 5.5.4：
Coronaviruses of nonhuman primates / 5.6：
Introduction to coronaviruses of nonhuman primates / 5.6.1：
Pathology of coronaviruses of nonhuman primates / 5.6.2：
Coronaviruses of ferrets and minks / 5.7：
Introduction to coronaviruses of ferrets and minks / 5.7.1：
Ferret enteric coronavirus / 5.7.2：
Ferret systemic coronavirus / 5.7.3：
Treatment options and protection against ferret coronavirus-induced diseases / 5.7.4：
Ferrets and feline infectious peritonitis virus of cats / 5.7.5：
Coronaviruses of minks / 5.7.6：
Coronaviruse of other musteloidea / 5.7.7：
Coronaviruses of rabbits / 5.8：
Rabbit enteric coronavirus / 5.8.1：
Rabbit coronavirus / 5.8.2：
Other rabbit coronaviruses / 5.8.3：
Coronaviruses of other wild or semidomesticated mammals / 5.9：
Coronaviruses of agricultural and companion animals with the potential for zoonotic transmission / 6：
Coronavirus genera and species / 6.1：
Severe acute respiratory syndrome coronaviruses, severe acute respiratory syndrome coronaviruses-2, and domesticated animals / 6.1.2：
MERS-CoV and domesticated animals / 6.1.3：
Diagnosis of coronaviruses of domesticated animals / 6.1.4：
Bovine coronavirus and its enteric and respiratory forms / 6.2：
Introduction to bovine coronaviruses / 6.2.1：
Pathology of bovine coronaviruses diseases and their underlying causes / 6.2.2：
Bovine coronaviruses-the viruses / 6.2.3：
Bovine enteric coronavirus / 6.2.4：
Bovine respiratory coronavirus / 6.2.5：
Bovine coronaviruses-like coronaviruses of other animals / 6.2.6：
Coronaviruses of dromedaries, llamas, and alpacas / 6.3：
Coronaviruses of dromedary camels / 6.3.1：
Coronaviruses of alpacas and llamas / 6.3.2：
Coronaviruses of swine / 6.4：
Introduction to swine coronaviruses / 6.4.1：
Pathology due to swine coronaviruses in general / 6.4.2：
The immune response to swine coronaviruses in general / 6.4.3：
Viral inhibition of the immune response to swine coronaviruses in general / 6.4.4：
Porcine epidemic diarrhea virus / 6.4.5：
Porcine deltacoronavirus / 6.4.6：
Porcine hemagglutinating encephalomyelitis virus / 6.4.7：
Swine acute diarrhea syndrome coronavirus / 6.4.8：
Transmissible gastroenteritis virus and porcine respiratory coronavirus / 6.4.9：
Coronavirus of horses / 6.5：
Introduction to coronaviruses of horses / 6.5.1：
Pathology due to coronavirus of horses / 6.5.2：
Coronaviruses of horses-the virus / 6.5.3：
Coronaviruses of sheep / 6.6：
Coronaviruses of companion animals / 6.7：
Coronaviruses of cats / 6.7.1：
Canine coronaviruses / 6.7.2：
Canine respiratory coronavirus / 6.7.3：
Brief overview of domestic avian coronaviruses / 6.8：
Pulling it all together: where do we go from here? / 7：
Coronaviruses-friends and family / 7.1：
Baltimore class IV viruses (coronaviruses' friends) / 7.1.1：
Coronaviridae (coronaviruses family) / 7.1.2：
Zoonotic transmission of coronaviruses / 7.2：
Coronaviruses proposed reservoir and intermediate hosts / 7.2.1：
Comparison between the hosts and geographical locations of severe acute respiratorysyndrome coronavirus- and severe acute respiratory syndrome coronavirus-2-like' viruses / 7.2.2：
Other animals as potential coronavirus reservoir hosts / 7.2.3：
Possible ways to predict and prevent future epidemics and pandemics / 7.3：
The One Health approach / 7.3.1：
SpillOver / 7.3.2：
Museums and emerging pathogens in the Americas (MEPA) / 7.3.3：
Factors driving zoonotic transmission / 7.4：
Viral factors driving zoonotic transmission / 7.4.1：
Host-related factors driving zoonotic transmission / 7.4.2：
Environmental factors driving zoonotic transmission / 7.4.3：
The "human factor" and modeling / 7.4.4：
The emergence and disease severity of severe acute respiratory system coronavirus-2 variants / 7.4.5：
The continuing threat of emerging infectious diseases / 7.5：
Changes in infectious disease patterns over the last ten years / 7.5.1：
The next pandemics-thinking outside of the box / 7.5.2：
Infectious diseases and the developing world / 7.6：
Author's note (March 2022) / 7.7：
Coronavirus disease overviews / Appendix I：
Glossary / Appendix II：
Index
List of figures
List of tables
Acknowledgments
9.

図書
図書
9. Composites and Advanced Materials Expo (CAMX 2022) : Anaheim, California, USA 17-20 October 2022 (v. 2)
Composites and Advanced Materials Expo ; Society for the Advancement of Material and Process Engineering
出版情報: Diamond Bar, California : SAMPE, 2023, c2022  p. 539-1084 ; 28 cm
所蔵情報: loading…
10.

図書
図書
10. Society for Biomaterials Annual Meeting and Exposition 2023 : riding the translational waves to the future : San Diego, California, USA 19-22 April 2023 (v. 2)
Society for Biomaterials. Meeting ; Society for Biomaterials
出版情報: Mount Laurel, NJ : Society for Biomaterials, c2023  p. 428-856 ; 28 cm
所蔵情報: loading…
文献の複写および貸借の依頼を行う
 文献複写・貸借依頼